Altimmune, Inc. (ALT)
| Market Cap | 583.55M +82.1% |
| Revenue (ttm) | 31,000 +55.0% |
| Net Income | -91.76M |
| EPS | -0.73 |
| Shares Out | 194.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,042,164 |
| Open | 2.940 |
| Previous Close | 2.940 |
| Day's Range | 2.900 - 3.020 |
| 52-Week Range | 2.560 - 6.440 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 17.22 (+474.0%) |
| Earnings Date | Aug 12, 2026 |
About ALT
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Financial Performance
In 2025, Altimmune's revenue was $41,000, an increase of 105.00% compared to the previous year's $20,000. Losses were -$88.09 million, -7.33% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price target is $17.22, which is an increase of 474.00% from the latest price.
News
Altimmune reports Q2 EPS (12c), consensus (12c)
“We have achieved several important milestones as we continue to successfully execute our strategy, including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the…
Altimmune Earnings Call Transcript: Q2 2026
Strong clinical and operational progress marked Q2 2026, with phase III MASH trial initiation and robust phase II AUD results for pemvidutide. Financials remain solid with $519M cash, supporting operations through 2029, while future AUD phase III funding will rely on non-dilutive options.
Altimmune Earnings release: Q2 2026
Altimmune released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Altimmune Quarterly report: Q2 2026
Altimmune has published its Q2 2026 quarterly earnings report on August 12, 2026.
Altimmune Slides: Corporate presentation
Altimmune has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash...
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today anno...
Altimmune initiates PERFORMA trial
Altimmune (ALT) announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the efficacy and safety of pemvidutide in patients with metabolic dysfunction-associate...
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes
Barclays says trial data highlights meaningful opportunity for Altimmune in AUD
Barclays analyst Eliana Merle notes Altimmune (ALT) reported topline data from the Phase 2 RECLAIM trial of pemvidutide for alcohol use disorder, demonstrating statistical-significance improvement acr...
H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune
H.C. Wainwright reiterates a Buy rating on Altimmune (ALT) with a $20 price target saying the company announced positive topline results from the Phase 2 RECLAIM trial evaluating pemvidutide in…
Leerink remains bullish on Altimmune following ‘positive’ AUD trial results
Leerink notes Altimmune (ALT) announced “positive topline results” from its Phase 2 RECLAIM trial of lead asset pemvidutide in patients with alcohol use disorder. Importantly, treatment with pemviduti...
Altimmune Transcript: Study result
Pemvidutide demonstrated robust efficacy in reducing heavy drinking days and achieving key FDA-recognized endpoints in moderate to severe AUD, with favorable safety and tolerability. The trial also showed potential liver benefits and significant weight loss, supporting further development in broader liver disease indications.
Altimmune Press release: Study result
Altimmune issued a press release on July 28, 2026, disclosing material business information to investors.
Altimmune Slides: Study result
Altimmune has posted slides in relation to its latest quarterly earnings report, which was published on July 28, 2026.
Altimmune announces RECLAIM trial met primary endpoint
Altimmune (ALT) announced topline results from the RECLAIM Phase 2 trial evaluating pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe a...
Altimmune's drug meets main goal of mid-stage study for alcohol use disorder
Altimmune said on Tuesday its experimental drug met the main goal of a mid-stage trial to help people with alcohol use disorder.
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, inc...
Altimmune initiated with an Outperform at Leerink
Leerink analyst Thomas Smith initiated coverage of Altimmune (ALT) with an Outperform rating and $10 price target Altimunne is an attractive play in an increasingly validated market for MASH therapeut...
Altimmune initiated with an Outperform at Leerink
Leerink initiated coverage of Altimmune (ALT) with an Outperform rating and $10 price target
Altimmune Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management emphasized strategic progress, financial strength, and differentiation of pemvidutide in the evolving MASH/NASH market. Phase III trials are set to begin enrollment in the second half of the year, with a readout expected in 2029. Expansion into AUD and ALD is underway, with key data readouts and updates anticipated next quarter.
Altimmune Transcript: Jefferies Global Healthcare Conference 2026
Phase III enrollment for pemvidutide in MASH is set for later this year, supported by strong EASL data and robust funding. The program leverages AI tools and flexible endpoints, aiming for differentiation in a growing market, with phase II AUD data expected soon.
Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide
Altimmune (ALT) announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated l...
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors
Altimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today annou...